Molecular Markers Panel for Prostate Cancer Screening

Apolihin O.I., Severin S.E., Sivkov A.V., Savvateeva M.V., Keshishev N.G., Shkabko O.V., Raevskaya A.A.

At present time the challenge of prostate cancer early detection becomes more and more vital due to prostate cancer (PCa) is one of the most common malignant tumors in males. Development and clinical introduction of programs of prostate cancer early detection is not only about a medical concern but about social and economic meaning for government. After introduction 20 years ago PSA test gave a start to early prostate cancer detection era, increased rate of localized curable cancer detection. This article reveals efficiency and specificity of test-system for early diagnostics and control of prostate cancer. This system consist of molecular markers DNA-marker, GST п1, RARp2, RASSF1A. The study was conducted on a biological material obtained from 157 men whose average age was 67,6 ± 7,7 years, PSA ranged from 4 to 10 ng/ml. Was formed 4 groups of patients: a group of patients with chronic prostatitis (30 patients), a group of patients with benign prostatic hyperplasia (55 patients), a group of patients with Pca (50 patients) and a group of conventionally healthy donors without identified pathology of prostate (22 person). Selected markers have sufficient high sensibility and specificity. Development of test-system based on selected molecular markers for diagnostics and control of prostate diseases potentially can survival rate and quality of life of a big group of population able to work. Effective research of such molecular genetic markers is possible only in terms of using of modern high informative methods of large-scale screening of genetic/genomic and epigenetic/ epigenomic abnormalities in malignant tumors specimens.

Download current article412.56 KB